During the past decade, MUDr. Alexandra Ludkova conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MUDr. Alexandra Ludkova" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "MUDr. Alexandra Ludkova" are "Heart Failure" (2 trials). Many other conditions were trialed in "MUDr. Alexandra Ludkova" in a lesser frequency.

Most popular intervention types in "MUDr. Alexandra Ludkova" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Empagliflozin" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "MUDr. Alexandra Ludkova" are 2 trials for "All" genders.

Currently, there are NaN active trials in "MUDr. Alexandra Ludkova". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in MUDr. Alexandra Ludkova, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MUDr. Alexandra Ludkova, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".